Fulcrum Therapeutics reports bigger Q4 net loss

Fulcrum Therapeutics

24/02/2026 12:17

Overview

Biopharmaceutical firm reported Q4 net loss of $20.3 mln

Company ended 2025 with $352.3 mln in cash, cash equivalents, and marketable securities

Announced positive 12-week results from Phase 1b PIONEER trial in sickle cell disease

Outlook

Fulcrum plans to initiate a registration-enabling trial for pociredir in H2 2026

Company expects cash runway to fund operations into 2029

Activating sites for open-label extension trial to evaluate pociredir's safety

Result Drivers

PIONEER TRIAL RESULTS - 20 mg dose cohort in Phase 1b PIONEER trial showed 12.2% increase in fetal hemoglobin, improvements in hemolysis and anemia markers

CASH POSITION - Ended 2025 with $352.3 mln in cash, cash equivalents, and marketable securities, providing runway into 2029

FUTURE TRIAL PLANS - Plans to initiate a potential registration-enabling trial in the second half of 2026, pending FDA feedback

Company press release: ID:nGNX1S9hHc

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$20.30 mln
Q4 Basic EPS
-$0.31


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Fulcrum Therapeutics Inc is $23.00, about 111.2% above its February 23 closing price of $10.89

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)